文献速递神经MR

深度学习MRI模型鉴别瘤样脱髓鞘病变与IDH野生型胶质母细胞瘤

Deep Learning MRI Models for the Differential Diagnosis of Tumefactive Demyelination versus IDH Wild-Type Glioblastoma.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-07-01

本研究纳入瘤样脱髓鞘病变144例和IDH野生型胶质母细胞瘤455例,利用3D DenseNet121架构基于增强T1加权和T2加权MRI构建深度学习模型进行鉴别。联合T1C和T2图像的前瞻性验证AUROC为88%(95%CI:0.82-0.95),模型评分阈值0.28时,正确分类瘤样脱髓鞘病变的敏感度为91%,特异度为80%(正确分类IDHwt GBM)。作者认为MRI可为深度学习模型辅助脑病变鉴别诊断提供基础,需进一步验证模型跨机构、人群和技术的泛化性及最佳分类阈值。

要点

  • 联合T1C和T2图像的深度学习模型前瞻性验证AUROC为88%(95%CI:0.82-0.95)。
  • 模型评分阈值0.28时,正确分类瘤样脱髓鞘病变的敏感度为91%,特异度为80%。
  • 分层AUROC提示按年龄和MRI采集方式选择阈值可能改善模型性能。

核心结论

  • MRI可为深度学习模型辅助脑病变鉴别诊断提供基础,需进一步验证模型跨机构、人群和技术的泛化性及最佳分类阈值。

研究设计与样本

  • 多阶段研究,采用3D DenseNet121架构,基于增强T1加权和T2加权MRI构建模型;瘤样脱髓鞘病变144例,IDHwt GBM 455例;第一阶段模型开发及5折交叉内部验证,第二阶段在独立IDHwt GBM上验证模型特异度,第三阶段对瘤样脱髓鞘病变和IDHwt GBM进行前瞻性验证;以分层AUROC评估模型性能。

诊断标准与关键数值

  • 联合T1C和T2图像的模型前瞻性验证AUROC为88%(95%CI:0.82-0.95);模型评分阈值0.28时,正确分类瘤样脱髓鞘病变的敏感度为91%,特异度为80%(正确分类IDHwt GBM);分层AUROC提示按年龄和MRI采集方式选择阈值可能改善模型性能。

临床应用与阅片要点

  • 作者认为MRI可为深度学习模型辅助脑病变鉴别诊断提供基础;需进一步验证模型跨机构、人群和技术的泛化性,并评估最佳分类阈值;下一步应纳入CNS淋巴瘤和脑转移瘤等其他肿瘤病因。

局限性

  • 需进一步验证以评估模型跨机构、患者人群和技术的泛化性。
  • 需进一步验证以评估最佳分类阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Diagnosis of tumefactive demyelination can be challenging. The diagnosis of indeterminate brain lesions on MRI often requires tissue confirmation via brain biopsy. Noninvasive methods for accurate diagnosis of tumor and nontumor etiologies allows for tailored therapy, optimal tumor control, and a reduced risk of iatrogenic morbidity and mortality. Tumefactive demyelination has imaging features that mimic isocitrate dehydrogenase wild-type glioblastoma (IDHwt GBM). We hypothesized that deep learning applied to postcontrast T1-weighted (T1C) and T2-weighted (T2) MRI can discriminate tumefactive demyelination from IDHwt GBM.

MATERIALS AND METHODS: Patients with tumefactive demyelination (n = 144) and IDHwt GBM (n = 455) were identified by clinical registries. A 3D DenseNet121 architecture was used to develop models to differentiate tumefactive demyelination and IDHwt GBM by using both T1C and T2 MRI, as well as only T1C and only T2 images. A 3-stage design was used: 1) model development and internal validation via 5-fold cross validation by using a sex-, age-, and MRI technology-matched set of tumefactive demyelination and IDHwt GBM, 2) validation of model specificity on independent IDHwt GBM, and 3) prospective validation on tumefactive demyelination and IDHwt GBM. Stratified area under the receiver operating curves (AUROCs) were used to evaluate model performance stratified by sex, age at diagnosis, MRI scanner strength, and MRI acquisition.

RESULTS: The deep learning model developed by using both T1C and T2 images had a prospective validation AUROC of 88% (95% CI: 0.82-0.95). In the prospective validation stage, a model score threshold of 0.28 resulted in 91% sensitivity of correctly classifying tumefactive demyelination and 80% specificity (correctly classifying IDHwt GBM). Stratified AUROCs demonstrated that model performance may be improved if thresholds were chosen stratified by age and MRI acquisition.

CONCLUSIONS: MRI can provide the basis for applying deep learning models to aid in the differential diagnosis of brain lesions. Further validation is needed to evaluate how well the model generalizes across institutions, patient populations, and technology, and to evaluate optimal thresholds for classification. Next steps also should incorporate additional tumor etiologies such as CNS lymphoma and brain metastases.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Conte GM, Moassefi M, Decker PA, et al. Deep Learning MRI Models for the Differential Diagnosis of Tumefactive Demyelination versus IDH Wild-Type Glioblastoma. AJNR Am J Neuroradiol. 2025. PMID: 39788628. doi:10.3174/ajnr.A8645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。